相关实验视频

Updated: Jun 27, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

基于Boruta-shap和RFC-RFECV算法对肺癌血清生物标志物的查

Guangcheng Yue¹

¹Department of Thoracic Surgery, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, China.

Journal of proteomics

|April 25, 2024

概括

这项研究确定了六种血清微RNA (miRNA) 作为肺癌诊断的潜在非侵入性生物标志物. 这些生物标志物显示出对肺癌敏感和特定的早期检测有前途.

科学领域:

生物标志物和诊断方法
基因组学和分子生物学
在瘤学瘤学.

背景情况:

肺癌是全球癌症相关死亡的主要原因之一.
微RNA (miRNA) 越来越多地被认为是癌症诊断和预后的有价值生物标志物.
准确和早期诊断肺癌对于改善患者的治疗结果至关重要.

研究的目的:

确定一组血清miRNA作为肺癌潜在的诊断生物标志物.
开发和验证用于选择信息性miRNAs的算法方法.
使用已识别的miRNAs建立非侵入性肺癌诊断的分类器.

主要方法:

分析了来自肺癌患者和对照者的血清miRNA表达数据.
使用Boruta-shap和RFC-RFECV算法来选择顶级特征miRNAs.
一个高斯的天真贝叶斯分类器被训练并使用交叉验证和ROC分析进行验证.

主要成果:

六种特定的miRNAs (hsa-miRNA-144,hsa-miRNA-107,hsa-miRNA-484,hsa-miRNA-103,hsa-miRNA-26b和hsa-miRNA-641) 被确定为关键的诊断标记物. 这两种类型的miRNAs都被认为是关键的诊断标记物.
开发的分类器实现了高诊断性能,在初始评估中AUC为0.8966,在验证集中为0.9345-0.9423
在验证队列中,诊断准确率达到89%,这表明有很大的潜力.

结论:

一个由六个血清miRNA组成的小组可以作为肺癌诊断的有效的非侵入性生物标志物.
算法方法有助于识别强大的miRNA签名用于癌症检测.
这些发现支持开发用于早期肺癌查的敏感和特定工具.

关键词:

波鲁塔的形状是波鲁塔的形状.诊断诊断诊断诊断诊断肺癌是一种肺癌.在RFC-RFECVV中,我们可以使用RFC.血清中的生物标志物

更多相关视频

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

相关概念视频

Serum Laboratory Studies, Stool Test, Breath Test

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...